Company Overview of Biovest International Inc.
Biovest International, Inc., a biotechnology company, develops therapeutic cancer vaccines in the United States. It operates in two segments, Instrumentation and Vaccine. The company develops and commercializes BiovaxID, a personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. It is also involved in the development, manufacture, and sale of instruments and disposables, including AutovaxID, an automated cell culture system that enables production of personalized cell-based treatments; HF Primer, a cell culture system for producing small quantities of the cell culture products from mammalian cell lines; and Multi-6, a cell culture system for producing small scale qu...
300 South Hyde Park Avenue
Tampa, FL 33606
Founded in 1981
Key Executives for Biovest International Inc.
Chief Executive Officer and President
Executive Chairman and Member of Compensation Committee
Director of Legal Affairs and Corporate Secretary
Compensation as of Fiscal Year 2016.
Biovest International Inc. Key Developments
Aytu Bioscience, Inc. Enters into a Master Services Agreement with Biovest International, Inc
Oct 13 15
On October 8, 2015, Aytu Bioscience Inc. entered into a Master Services Agreement with Biovest International Inc., pursuant to which Biovest is to provide manufacturing services to Aytu. The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. The agreement provides customary terms and conditions, including those for performance of services by Biovest in compliance with project addendums, industry standards, regulatory standards and all applicable laws. Biovest will be responsible for obtaining and maintaining all governmental approvals, at Aytu's expense, during the term of the agreement. The agreement has a term of four years, provided that either party may terminate the agreement or any project addendum under the agreement on 30 days written notice of a material breach under the agreement. In addition, Aytu may terminate the agreement or any project addendum under the agreement upon 180 days written notice for any reason.
Biovest International Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 11:45 AM
Nov 20 14
Biovest International Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 11:45 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries